Burney Co. Sells 12,005 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Burney Co. cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 50.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,917 shares of the biotechnology company's stock after selling 12,005 shares during the period. Burney Co.'s holdings in United Therapeutics were worth $3,674,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the last quarter. Hohimer Wealth Management LLC grew its holdings in United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after acquiring an additional 37 shares during the period. Florida Financial Advisors LLC grew its holdings in United Therapeutics by 6.2% during the 4th quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock worth $290,000 after acquiring an additional 48 shares during the period. Dunhill Financial LLC grew its holdings in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares during the period. Finally, Two Sigma Investments LP grew its holdings in United Therapeutics by 3.0% during the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company's stock worth $626,000 after acquiring an additional 52 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock valued at $24,628,589 over the last 90 days. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 0.6%

Shares of NASDAQ:UTHR traded down $1.91 during mid-day trading on Friday, reaching $304.50. The company had a trading volume of 310,921 shares, compared to its average volume of 372,488. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The firm has a market cap of $13.74 billion, a price-to-earnings ratio of 12.15, a PEG ratio of 6.68 and a beta of 0.53. The company's 50-day moving average price is $300.01 and its 200-day moving average price is $316.20.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period in the previous year, the business earned $6.17 EPS. United Therapeutics's revenue was up 17.2% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. UBS Group cut their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Morgan Stanley cut their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.